CompletedPhase 2NCT00498654
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
Studying Typhoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Avant Immunotherapeutics
- Principal Investigator
- Clark McKeever, MDAccelovance LLC
- Intervention
- Ty800 (Salmonella typhi) Oral Vaccine(biological)
- Enrollment
- 180 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2007 – 2008
Study locations (5)
- Accelovance LLC, San Diego, California, United States
- Accelovance LLC, Melbourne, Florida, United States
- Accelovance LLC, Peoria, Illinois, United States
- Accelovance LLC, South Bend, Indiana, United States
- Accelovance LLC, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00498654 on ClinicalTrials.govOther trials for Typhoid
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950Induction of Gut Permeability by an Oral VaccineUSDA, Western Human Nutrition Research Center
- ACTIVE NOT RECRUITINGPHASE3NCT03299426Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, MalawiUniversity of Maryland, Baltimore
- ACTIVE NOT RECRUITINGPHASE4NCT03970304CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated AdultsUniversity of Maryland, Baltimore